Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
According to many studies, breast cancer is more common in women whose family members or blood relatives have also had breast cancer. This means that it is mostly genetic. Other factors like Radiation exposure, obesity, alcohol consumption, not having children, can all participate as risk factors fo....
Be thankful if you are lactose intolerant because it could save you from certain cancers including breast cancer. Some researchers from Sweden said in 2014 that people who are lactose intolerant might be less likely to develop lung, breast and ovarian cancers. Low dairy consumption seems to reduce t....
Some cancer treatments, like chemotherapy, radiation, or certain surgeries, can affect fertility, but it depends on the type of cancer, the treatment, and your age. If having children in the future is important to you, bring this up with your doctor before starting treatment. There are options to pr....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.